Daniel E. Castellano
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 268 publications
Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.
Journal: Cancer treatment and research communications
Published: May 03, 2026
The combination of atezolizumab and BCG in high-risk non-muscle invasive bladder cancer: results of the phase Ib/II BladderGATE clinical trial.
Journal: The oncologist
Published: March 20, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 21, 2026
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 20, 2026
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.
Journal: Lancet (London, England)
Published: February 09, 2026
Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective study.
Journal: Urologic oncology
Published: December 09, 2025
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 14, 2025
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.
Journal: The New England journal of medicine
Published: October 22, 2025
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 25, 2025
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial.
Journal: European urology oncology
Published: September 22, 2025
CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder cancer.
Journal: Scientific reports
Published: September 02, 2025
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.
Journal: Nature communications
Published: July 25, 2025
Last Updated: 09/26/2026